









Markets
/
Stocks
/
nasdaq-prpo
/

Precipio Inc

PRPO

16.690USD

-0.880-5.01%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

25.31MMarket Cap

LossP/E TTM



Precipio Inc

16.690

-0.880-5.01%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

147 / 207

Overall Ranking

438 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 96.90% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 18.53M.

Undervalued

The company’s latest PE is -14.13, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 319.42K shares, increasing 6.80% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 17.64K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.14.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 4.51, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 5.65M, representing a year-over-year increase of 27.31%, while its net profit experienced a year-over-year increase of 106.07%.

Score

Industry at a Glance

Previous score

4.51

Change



Financials

4.97

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.51

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -14.88, which is -91.14% below the recent high of -1.32 and 79.57% above the recent low of -3.04.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 147/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Healthcare Equipment & Supplies industry's average is 7.70.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.20, which is higher than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 21.95 and the support level at 13.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.20

Change

-0.19

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.524

Neutral

RSI(14)

48.013

Neutral

STOCH(KDJ)(9,3,3)

17.166

Sell

ATR(14)

1.522

Low Volatility

CCI(14)

-61.022

Neutral

Williams %R

70.280

Sell

TRIX(12,20)

1.210

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

17.789

Sell

MA10

19.211

Sell

MA20

17.313

Sell

MA50

15.582

Buy

MA100

12.752

Buy

MA200

9.588

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 21.11%, representing a quarter-over-quarter increase of 3.89%. The largest institutional shareholder is The Vanguard, holding a total of 17.64K shares, representing 1.09% of shares outstanding, with 8.48% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Eklund (David A)

84.25K

Cohen (David Seth)

52.05K

+4.71%

BlackRock Institutional Trust Company, N.A.

28.91K

AMH Equity, Ltd.

38.29K

Sandberg (Richard A)

25.18K

+248.20%

The Vanguard Group, Inc.

Star Investors

17.64K

Andrews (Ronald Asbury)

14.55K

+13.98%

Geode Capital Management, L.L.C.

15.10K

+4.41%

Cossman (Jeffrey M.D.)

14.03K

LaPorte (Kathleen D)

12.30K

+22.16%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.20, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.